Journal of Pharmaceutical Technology & Drug Research

Journal of Pharmaceutical Technology &
Drug Research

ISSN 2050-120X
Original Research

The use of a combination of tamoxifen and doxorubicin synergistically to induce cell cycle arrest in BT483 cells by down-regulating CDK1, CDK2 and cyclin D expression

Pei-Yun Chuang1, Cheng Huang2 and Hsiu-Chen Huang1*

*Correspondence: Hsiu-Chen Huang jane@mail.nhcue.edu.tw

1. Department of Applied Science, National Hsinchu University of Education, Hsinchu 30014, Taiwan.


Author Affiliations

2. National Research Institute of Chinese Medicine, Taipei 11221, Taiwan.

Abstract

Background: Tamoxifen and Doxorubicin are used alone or in combination to treat breast cancer. Although these drugs have been utilized in combination, the advantage of their combination, in terms of therapeutic efficacy, still remains controversial.

Methods: Cells were treated with Tamoxifen alone and doxorubicin alone or treated with both Tamoxifen and doxorubicin, cell cycle distribution, cell cycle regulatory protein, mRNA, and activity were measured.

Results: This study uses breast cancer cell lines to demonstrate the synergistic interaction between Doxorubicin and Tamoxifen, and to explain the CDK1 and CDK2 expression underlying the synergy. This study demonstrates that the combination of Doxorubicin and Tamoxifen significantly reduces the growth of ER-positive breast cancer cells and that this is driven primarily by the enhanced effect of the decreased protein expression of the CDK1, CDK2 and cyclin D. It is also proposed that selective modification of AKT inactivation, ERK activation probably contributes to the synergistic interaction.

Conclusions: Overall, the findings suggest that a combination of Doxorubicin and Tamoxifen could be effective in the treatment of ER-positive breast cancers, so this combination warrants further investigation.

Keywords: Tamoxifen, doxorubicin, BT483 cells, CDK1, CDK2

ISSN 2050-120X
Volume 2
Abstract Download